Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502292 | 1.00 | NLRP3 (0.45) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| SCHEMBL29478100 | 1.00 | NLRP3 (0.45) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| SCHEMBL22113081 | 1.00 | NLRP3 (0.45) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| Hydrochloric Acid SCHEMBL28551850 | 0.98 | NLRP3 (0.44) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| Hydrochloric Acid SCHEMBL3999288 | 0.98 | NLRP3 (0.44) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| Hydrochloric Acid SCHEMBL30655761 | 0.98 | NLRP3 (0.44) | NLRP3KMT2AMEN1AKR1B1IDO1 | |
| SCHEMBL30765055 | 0.84 | MEP1B (0.43) | NLRP3KMT2AMEN1NOS3NOS1 | |
| SCHEMBL10064650 | 0.84 | MEP1B (0.43) | NLRP3KMT2AMEN1NOS3NOS1 | |
| SCHEMBL27125027 | 0.84 | MEP1B (0.43) | NLRP3KMT2AMEN1NOS3NOS1 | |
| SCHEMBL23470803 | 0.84 | CA12 (0.45) | AKR1B1IDO1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| US-11345669-B2 | Urea derivatives and methods of use thereof | NodThera Limited (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | NodThera Limited (GB) | 2020-04-30 | — | — | US | disclosed |
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
| EP-0999856-B1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| CN-1239895-A | Radiopharmaceuticals for imaging sites of infection and inflammation | DU PONT MERCK PHARMA (US) | 1999-12-29 | — | — | CN | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | NLRP3 743/4885KMT2A 4348/4885MEN1 2818/4885 |
| US-20200131141-A1 | CHEMICAL COMPOUNDS | IL1B, CASP1, IL1A | NLRP3 4/4885KMT2A 4501/4885MEN1 888/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | NLRP3 88/4885KMT2A 4021/4885MEN1 4015/4885 |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | NLRP3 743/4885KMT2A 4348/4885MEN1 2818/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | NLRP3 4037/4885KMT2A 1632/4885MEN1 3773/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | NLRP3 1615/4885KMT2A 4810/4885MEN1 4557/4885 |
| US-11345669-B2 | Urea derivatives and methods of use thereof | IL1B, IL1A, NOD1 | NLRP3 5/4885KMT2A 4408/4885MEN1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.